Published in the Red Journal, this MD Anderson study reported on the interim analysis of acute and late toxicities and cosmetic outcomes after proton APBI for 100 patients with pTis or pT1-2 N0 (≤3cm) breast cancer.

With a median follow-up of 24 months, this study reported no acute or late toxicities of grade 3 or higher; no patients experienced fat necrosis, fibrosis, infection, or breast shrinkage. Excellent or good cosmesis at 12 months was reported by 91% of patients and 94% of physicians. Proton APBI is a maturing treatment option with high local control, favorable intermediate term cosmesis, high treatment satisfaction, low treatment burden, and exceptional heart and lung sparing.